bioRxiv Science⌕ Search

Biology subjects

Belmonte-Reche, E.

Publications and source records attributed to Belmonte-Reche, E..

2 recordsLinked to original sources

BMAL1 represses transposable elements independently of CLOCK in pluripotent cells

Circadian oscillations of gene transcripts rely on a negative feedback loop executed by the activating BMAL1-CLOCK heterodimer and its negative regulators PER and CRY. Although circadian rhythms and CLOCK protein are mostly absent during embryogenesis, the lack of BMAL1 during prenatal development causes an early aging phenotype during adulthood, suggesting that BMAL1 carries out an unknown non-circadian function during organism development that is fundamental for healthy adult life. Here, we show that BMAL1 interacts with TRIM28 and represses transcription of totipotency-associated MERVL retrotransposons in mouse pluripotent cells. Deletion of Bmal1 leads to genome-wide upregulation of MERVLs, changes in the three-dimensional organization of the genome, and acquisition of totipotency-associated features. Overall, we demonstrate that in pluripotent cells BMAL1 is redeployed as a transcriptional repressor of transposable elements (TEs) in a CLOCK-independent way. We propose that BMAL1-TRIM28 activity during prenatal life is essential for optimal health and life span in mammals.

molecular biology↗

EZH2 represses mesenchymal genes and upholds epithelial identity in breast cancer cells

Emerging studies support that the Polycomb Repressive Complex 2 (PRC2) regulates phenotypic changes of carcinoma cells by modulating their shifts among metastable states within the epithelial and mesenchymal spectrum. This new role of PRC2 in cancer has been recently proposed to stem from the ability of its catalytic subunit EZH2 to bind and modulate the transcription of mesenchymal genes during epithelial-mesenchymal transition (EMT) in lung cancer cells. Here, we asked whether this mechanism is conserved across different types of carcinomas. By combining TGF-{beta}-mediate reversible induction of epithelial to mesenchymal transition and pharmacological inhibition of EZH2 activity we demonstrate that EZH2 represses a large set of mesenchymal genes and favours the residence of breast cancer cells towards the more epithelial spectrum during EMT. In agreement, analysis of human patient samples support that EZH2 is required to efficiently repress mesenchymal genes in breast cancer tumours. Our results indicate that PRC2 operates through similar mechanisms in breast and lung cancer cells. We propose that PRC2-mediated direct transcriptional modulation of the mesenchymal gene expression program is a conserved molecular mechanism underlying cell dissemination across human carcinomas.

cancer biology↗